UCB Pharma
Belgium - BrusselsPharmaceutical
Focus: UCB Pharma is a Brussels-based specialty pharmaceutical company focusing on small molecules and biologics across neurology, immunology, oncology, dermatology, and respiratory indications. The company generates 62% of revenue from its TNF-blocker CIMZIA, indicating heavy reliance on a maturing asset.
Profile data last refreshed 56m ago · AI intelligence enriched 2w ago
Open Jobs
0
About UCB Pharma
AI assessmentNot HiringNo open roles listed right now. Follow UCB Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from UCB Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthWatch
Pipeline
Early-stage
50 total
LOE Risk
2 imminent
KEPPRA XR
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$275M Part DDeclining
LOE Approaching
Cornerstone product generating 62% of company revenue; approaching loss of exclusivity creates urgent need for pipeline transition.
Help build intelligence for UCB Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.